NasdaqGM - Nasdaq Real Time Price USD

SIGA Technologies, Inc. (SIGA)

8.79

+0.15

(+1.74%)

At close: April 26 at 4:00 PM EDT

8.79

0.00

(0.00%)

After hours: April 26 at 5:44 PM EDT

SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian). Effective June 1, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key c

GlobeNewswire 25 days ago
SIGA Names Larry Miller General Counsel

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. “With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving

GlobeNewswire last month
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023

• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. “In 2023, SIGA had approximately $131 million in produc

GlobeNewswire last month
SIGA Declares Special Cash Dividend of $0.60 Per Share

Represents a $0.15 Per Share Increase Over 2023 Special DividendNEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company’s common stock. This represents an increase of $0.15 per share, or 33%, over the cash dividend paid in June 2023. The dividend is payable on April 11, 2024, to shareholders of record at the

GlobeNewswire last month
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 12th, 2024. Participating in the call will be Dr. Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at www.siga.com unde

GlobeNewswire last month
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company’s Board of Directors. SIGA’s current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024. “The appointment of Diem Nguyen as our new CEO marks a signi

GlobeNewswire 3 months ago
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023

- In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® - - In October, Joint Procurement Framework Contract was signed by European Commission with Anticipated Initial Orders by Participating Countries of Approximately $18 Million for Oral TPOXX® (Tecovirimat) - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-s

GlobeNewswire 5 months ago
SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, November 7th, 2023. Participating on the call will be Phil Gomez, Chief Executive Officer, Dennis Hruby, Chief Scientific Officer, Dr. Jay Varma, Chief Medical Officer and Daniel Luckshire, Chief Financial Officer. A live webcast of the

GlobeNewswire 5 months ago
SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the creation by the European Commission’s DG HERA (Health Emergency Preparedness and Response Authority) of a joint procurement mechanism under which 13 participating countries from the European Union (EU) and the European Free Trade Association (EFTA) can efficiently order oral TPOXX. Based on commitments from

GlobeNewswire 6 months ago
SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO). He will also continue to serve as a director of the SIGA Board of Directors. “As SIGA has worked to support the global response to the MPOX outbreak and as we continue to expand our role in planning for the preve

GlobeNewswire 7 months ago
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023

- In July, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2023. “SIGA’s second quarter financial results reflect the continuation of international sales activity that

GlobeNewswire 8 months ago
SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®

Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current Contract reflects continuing global action to enhance smallpox preparednessNEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services exercised procurement options for the delivery of approximately $113 million worth of o

GlobeNewswire 8 months ago
SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 8th, 2023. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Dr. Dennis Hruby, Chief Scientific Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on

GlobeNewswire 8 months ago
SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium

Inaugural meeting on June 28-30, 2023, to include updates from leading experts on strategies to plan for and address broad range of potential global health risks including biological and viral disease outbreaks.NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that SIGA CEO Phil Gomez, PhD, will present an overview of the role of therapeutics in global plannin

GlobeNewswire 9 months ago
SIGA Reports Financial Results for Three Months Ended March 31, 2023

- Corporate Update Conference Call Today at 4:30 PM ET -NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2023. “First quarter product revenues primarily reflect the sale of oral TPOXX to the U.S. Department of Defense (“DoD”), which marks the third product delivery to the DoD within the past twelve months,” said Phil Gomez, CEO of SIGA. “Includ

GlobeNewswire 11 months ago
SIGA Declares Special Cash Dividend of $0.45 Per Share

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special cash dividend of $0.45 per share on the common stock of the Company. The special cash dividend is payable on June 1, 2023 to shareholders of record at the close of business on May 16, 2023. Phil Gomez, CEO of SIGA, commented, “Based on the Company’s current cash resources and strong balance sheet, we ar

GlobeNewswire 11 months ago

Performance Overview

Return	SIGA	S&P 500
YTD	+68.51%	+6.92%
1-Year	+83.05%	+25.26%
3-Year	+51.81%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SIGA Technologies, Inc. (SIGA)

SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®

SIGA Names Larry Miller General Counsel

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023

SIGA Declares Special Cash Dividend of $0.60 Per Share

SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results

SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023

SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results

SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023

SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®

SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results

SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium

SIGA Reports Financial Results for Three Months Ended March 31, 2023

SIGA Declares Special Cash Dividend of $0.45 Per Share

Performance Overview